Nivalis Therapeutics, which is developing a complementary small molecule therapy for cystic fibrosis, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering.
Nivalis lists several biotechs developing therapies for cystic fibrosis, including Galapagos (GLPG), which could raise over $250 million in its US IPO this week.
The Boulder, CO-based company was founded in 2007 and plans to list on the NASDAQ under the symbol NVLS. It initially filed confidentially on February 13, 2015. Cowen & Company and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
